Results 231 to 240 of about 41,710 (302)
Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia. [PDF]
Harris DD +7 more
europepmc +1 more source
ABSTRACT Gallic acid (GA), a plant‐derived phenolic compound, is evolving from a general antioxidant into a specific molecular modulator and a functional building block for advanced biomedical materials. This review synthesizes recent insights underpinned by GA's “redox duality”—its capacity to act as either a radical scavenger or a pro‐oxidant.
Woo Hyun Park
wiley +1 more source
ABSTRACT Aim Adverse events (AEs) detected in tweets and in the FDA Adverse Event Reporting System (FAERS) provide valuable insights into patient experiences with oral hypoglycemic agents including sodium‐glucose transporter 2 (SGLT2) and dipeptidyl peptidase‐4 (DPP4) inhibitors. This study compared the side effects identified from tweets with those in
Se‐Hoon Oh +2 more
wiley +1 more source
Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study. [PDF]
Yang YS +4 more
europepmc +1 more source
Quality control of protein import into mammalian mitochondria
Abstract Mitochondrial function depends on the continuous import of hundreds of nuclear‐encoded proteins. Targeting and translocation of mitochondrial proteins is a multistep process that is inherently vulnerable to defects in cytosolic quality control systems as well as perturbations in mitochondrial protein import machinery and organelle function ...
Madeleine Goldstein +2 more
wiley +1 more source
Sex‐specific 24‐hour minimum heart rate (MHR) stratification in patients with type 2 diabetes mellitus and essential hypertension (T2DM‐EH). Three key findings are shown from subgroup analysis: (1) In the normal MHR group (Group B), advancing age independently predicts reduced deceleration capacity (DC) in both sexes.
Pingping Wu +6 more
wiley +1 more source
Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus. [PDF]
Yoneda C, Kobayashi J, Kuribayashi N.
europepmc +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein +8 more
wiley +1 more source

